NCT05301517Phase 3Completed

A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies

Study sponsor: Kyntra Bio

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2023-04-03Actual

Enrollment · participants159Actual

Source updated2023-06-06Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Chemotherapy Induced Anemia

Treatments or interventions studied

SEPO®DrugAlso known as Recombinant human erythropoietin-α [rHuEPO-α]
RoxadustatDrugAlso known as FG-4592

Primary outcomes · main study measures

measure: Change in Hemoglobin (Hb) Level From Baseline to the Level Averaged Over Weeks 9-13; description: Hb levels measured from Weeks 9 through 13 will be averaged in order to provide a single measure for comparison to the baseline Hb levels.; timeFrame: Baseline, Weeks 9 through 13

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history